Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PRKX | P51817 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613074 | 0.90 | PRKCZ (0.44) | PRKCZCHRM1ROCK1ROCK2PRKX | |
| SCHEMBL25613062 | 0.89 | JAK3 (0.39) | FEN1PRKCZJAK3ROCK1ROCK2 | |
| SCHEMBL25613085 | 0.87 | ROCK1 (0.41) | FEN1PRKCZJAK3ROCK1ROCK2 | |
| SCHEMBL25613086 | 0.86 | JAK3 (0.46) | FEN1JAK3ROCK1 | |
| SCHEMBL25613075 | 0.86 | JAK3 (0.43) | FEN1JAK3ROCK1 | |
| SCHEMBL25613082 | 0.85 | JAK3 (0.48) | FEN1JAK3ROCK1 | |
| SCHEMBL25613060 | 0.85 | TTK (0.38) | FEN1JAK3 | |
| SCHEMBL25613078 | 0.84 | PIK3CD (0.33) | FEN1JAK3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25613190 | 0.83 | CTSD (0.32) | FEN1JAK3 | |
| SCHEMBL25613083 | 0.82 | LRRK2 (0.40) | JAK3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | FEN1 1864/4885PRKCZ 1069/4885JAK3 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.